![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Actavis Group Ptc Ehf Hafnarfjordur Is, based in Ireland, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their significant offerings is Repaglinide, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2010-304 - Rev 01
This Chemical Type CEP, issued on February 16, 2017, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 2135 associated with this CEP further emphasizes